Antineoplastic Lyophilized Powder Injection / Daunorubicin Hydrochloride Injection
20mg Anti cancer
Product : Daunorubicin Hydrochloride for Injection
Specification : Lyophilized, 20mg
Standard : BP, USP
Packing : 10 vials/box
Doxorubicin Hydrochloride for Injection, is a sterile red-orange
lyophilized powder for intravenous use only, is available in 10, 20
and 50 mg single dose vials.
Indication and dosage :
For remission induction in acute nonlymphocytic leukemia
(myelogenous, monocytic, erythroid) of adults and for remission
induction in acute lymphocytic leukemia of children and adults.
To treat acute lymphocytic leukemia
45 mg/m2 daily for first 3 days of a 32-day course of vincristine,
prednisone, and asparaginase combination therapy
To treat acute nonlymphocytic leukemia
45 mg/m2 daily for first 3 days of first course of cytarabine
combination therapy and first 2 days of second course of cytarabine
Daunorubicin is an antineoplastic in the anthracycline class.
General properties of drugs in this class include: interaction with
DNA in a variety of different ways including intercalation
(squeezing between the base pairs), DNA strand breakage and
inhibition with the enzyme topoisomerase II. Most of these
compounds have been isolated from natural sources and antibiotics.
However, they lack the specificity of the antimicrobial antibiotics
and thus produce significant toxicity. The anthracyclines are among
the most important antitumor drugs available. Doxorubicin is widely
used for the treatment of several solid tumors while daunorubicin
and idarubicin are used exclusively for the treatment of leukemia.
Daunorubicin may also inhibit polymerase activity, affect
regulation of gene expression, and produce free radical damage to
DNA. Daunorubicin possesses an antitumor effect against a wide
spectrum of tumors, either grafted or spontaneous. The
anthracyclines are cell cycle-nonspecific.
Mechanism of action
Daunorubicin has antimitotic and cytotoxic activity through a
number of proposed mechanisms of action: Daunorubicin forms
complexes with DNA by intercalation between base pairs, and it
inhibits topoisomerase II activity by stabilizing the
DNA-topoisomerase II complex, preventing the religation portion of
the ligation-religation reaction that topoisomerase II catalyzes.